Top Markets
Coin of the day
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Rang în acțiuni #20198
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Preț acțiune
$10.25
Ultima sincronizare: 2024-02-22
Capitalizare de piață
$137.83M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
CN
Tranzacționează Gracell Biotechnologies Inc. (GRCL)

Categorie

EPS pentru Gracell Biotechnologies Inc. (GRCL)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Gracell Biotechnologies Inc., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru Gracell Biotechnologies Inc. din 2026 până în 2026
EPS la sfârșitul fiecărui an
An EPS Schimbă
Nu sunt suficiente date pentru perioada selectată.
EPS pentru companii similare sau concurente
Companie EPS Diferență EPS Țara
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH